These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7339332)

  • 41. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
    Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
    Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapy of myasthenia gravis; clinical experiences with the treatment of myasthenia gravis pseudoparalytica with pyridostigmine].
    SEIBERT P
    Dtsch Med Wochenschr; 1953 May; 78(22):805-7. PubMed ID: 13067995
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of myasthenia gravis; prolonged action with multiple-dose tablets of neostigmine bromide and mestinon bromide.
    SCHWAB RS; OSSERMAN KE; TETHER JE
    J Am Med Assoc; 1957 Oct; 165(6):671-4. PubMed ID: 13462827
    [No Abstract]   [Full Text] [Related]  

  • 44. EFFECT OF EMOTIONS ON USE OF MEDICATION IN MYASTHENIA GRAVIS.
    CLAMAN L; JOHNSTONE RE
    Tex State J Med; 1965 Jan; 61():49-51. PubMed ID: 14226987
    [No Abstract]   [Full Text] [Related]  

  • 45. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
    Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
    J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia gravis.
    Gehi A; Benatar M; Langberg J
    J Cardiovasc Electrophysiol; 2008 Feb; 19(2):214-6. PubMed ID: 17711430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recovery from myasthenic crisis after use of IVIG therapy.
    Jain K; Passi GR; Rajguru M; Athle S; Gandhi DM
    Indian Pediatr; 1998 Sep; 35(9):901-3. PubMed ID: 10216601
    [No Abstract]   [Full Text] [Related]  

  • 48. Neostigmine: Not Only for the Operating Room.
    Gravino D; McNierney-Moore A
    J Emerg Nurs; 2018 Jan; 44(1):94-96. PubMed ID: 29306428
    [No Abstract]   [Full Text] [Related]  

  • 49. [MYASTHENIA GRAVIS].
    VAN HOVE
    Belg Tijdschr Geneesk; 1965 Jan; 21():81-4. PubMed ID: 14273382
    [No Abstract]   [Full Text] [Related]  

  • 50. Effects of neostigmine and pyridostigmine on serum cholinesterase activity.
    Mirakhur RK; Lavery TD; Briggs LP; Clarke RS
    Can Anaesth Soc J; 1982 Jan; 29(1):55-8. PubMed ID: 7055744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gulf War illness: Effects of repeated stress and pyridostigmine treatment on blood-brain barrier permeability and cholinesterase activity in rat brain.
    Amourette C; Lamproglou I; Barbier L; Fauquette W; Zoppe A; Viret R; Diserbo M
    Behav Brain Res; 2009 Nov; 203(2):207-14. PubMed ID: 19433115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative determination of Orlistat (tetrahydrolipostatin, Ro 18-0647) in human plasma by high-performance liquid chromatography coupled with ion spray tandem mass spectrometry.
    Bennett PK; Li YT; Edom R; Henion J
    J Mass Spectrom; 1997 Jul; 32(7):739-49. PubMed ID: 9241856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome.
    Filler G; Gow RM; Nadarajah R; Jacob P; Johnson G; Zhang YL; Christians U
    Pediatrics; 2006 Nov; 118(5):e1563-8. PubMed ID: 17015495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
    Henze T; Nenner M; Michaelis HC
    J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Side effects of low-dose pyridostigmine bromide are not related to cholinesterase inhibition.
    Cook MR; Gerkovich MM; Sastre A; Graham C
    Aviat Space Environ Med; 2001 Dec; 72(12):1102-6. PubMed ID: 11763111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiac dysrhythmia following reversal of neuromuscular blocking agents in geriatric patients.
    Owens WD; Waldbaum LS; Stephen CR
    Anesth Analg; 1978; 57(2):186-90. PubMed ID: 565156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans.
    Marino MT; Schuster BG; Brueckner RP; Lin E; Kaminskis A; Lasseter KC
    J Clin Pharmacol; 1998 Mar; 38(3):227-35. PubMed ID: 9549661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [MYASTHENIAS: THYMECTOMY AND SPIRONOLACTONES].
    DEVIC M; THIVOLET J; MICHET F; LENGLET JP; MAILLET P
    Rev Otoneuroophtalmol; 1964; 36():169-74. PubMed ID: 14219300
    [No Abstract]   [Full Text] [Related]  

  • 59. Myasthenic crisis--your assessment counts.
    Hickey JV
    RN; 1991 May; 54(5):54-9. PubMed ID: 2028194
    [No Abstract]   [Full Text] [Related]  

  • 60. Physiological and performance effects of pyridostigmine bromide in healthy volunteers: a dose-response study.
    Cook MR; Graham C; Sastre A; Gerkovich MM
    Psychopharmacology (Berl); 2002 Jul; 162(2):186-92. PubMed ID: 12110996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.